- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is testing new combinations of medicines to treat a type of head and neck cancer that has come back or spread. Doctors are looking at how well these new treatments shrink the cancer and if they are safe.
For: Head and Neck Squamous Cell CarcinomaFrance · Italy · Spain - Active not recruitingPHASE2
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is looking at a new treatment called tislelizumab, sometimes combined with other medicines, for head and neck cancer that has come back or spread. The aim is to see if it can shrink tumours and if it's safe for patients.
For: Head and Neck Squamous Cell Carcinoma · Head and Neck CancerUnited States · Australia · Canada - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
This study looks at new drug combinations (BGB-A425, LBL-007, and Tislelizumab) for advanced head and neck, kidney, and lung cancers. It aims to find safe doses and see if they shrink tumours. It's an early-stage study.
For: Head and Neck Squamous Cell Cancer · Renal Cell Carcinoma · Non-Small Cell Lung CancerFrance · Spain · Poland